Press Releases and Position Statements

MARCH 15	Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
MARCH 5	Takeda Submits New Drug Application to Import and Distribute Moderna’s COVID-19 Vaccine Candidate in Japan
FEBRUARY 24	Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan
JANUARY 21	Start of a Japanese Clinical Study of TAK-919, Moderna’s COVID-19 Vaccine Candidate
DECEMBER 2	COVID-19 and the Role of Diagnostic Testing for Asymptomatic and Pre-Symptomatic Individuals
DECEMBER 1	World’s Leading Life Science Companies Now Enrolling COMMUNITY, A Global Platform Trial For Hospitalized Patients with COVID-19
OCTOBER 29	Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan
OCTOBER 9	First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
OCTOBER 1	19 Organizations from the Healthcare Community Unite to Form COVID-19 Testing Industry Consortium
AUGUST 7	Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
AUGUST 3	Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial
MAY 26	Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation
MAY 7	CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration
APRIL 6	Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
MARCH 25	Takeda Research & Development and COVID-19
MARCH 23	Coronavirus and Product Supply
MARCH 4	Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19